Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma

Kim, H.; Ahn, Sungyoon; Hong, Suk Kyun; Yoon, Kyung Chul; Kim, Hee-Soo; Choi, Young Rok; Lee, H. W.; Yi, Nam Joon; Lee, K.‐W.; Suh, Kyung‐Suk

doi:10.1002/bjs.10541

Cited by 69 publications

(57 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yin et al conducted the only randomised controlled trial to compare the efficacy of liver resection with TACE in resectable intermediate HCC. Consistent with many retrospective studies, their results supported that liver resection could provide a better overall survival (OS) . In our recent study, we demonstrated that liver resection could provide similar OS and disease‐free survival for patients with multiple tumours meeting Milan criteria and those with multiple tumours beyond Milan but within up‐to‐seven criteria .…”

supporting

confidence: 85%

Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma—authors’ reply

Wang

Zhong

Mao

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

supporting

confidence: 85%

Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma—authors’ reply

Wang

Zhong

Mao

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Although the current BCLC guidelines recommend surgery only for BCLC‐A HCC, hepatobiliary surgeons have questioned whether resection of HCC should be undertaken in selected patients with BCLC‐B tumours. Indeed, an increasing number of studies have reported acceptable outcomes after resection for BCLC‐B HCC, suggesting that liver resection may be justified beyond the BCLC resection criteria in selected patients. For example, Wada and colleagues reported a 5‐year OS rate of 63·4 per cent after liver resection for multinodular BCLC‐B HCC.…”

Section: Discussionmentioning

confidence: 99%

“…For example, Wada and colleagues reported a 5‐year OS rate of 63·4 per cent after liver resection for multinodular BCLC‐B HCC. Kim and co‐workers reported superior outcomes with resection versus non‐surgical treatment for BCLC‐B HCC in a propensity score‐matched analysis (5‐year OS: 63 versus 22 per cent). In another study, resection of multinodular HCC was associated with an acceptable 5‐year OS rate of 57 per cent among patients with BCLC‐B disease.…”

Section: Discussionmentioning

confidence: 99%

Hepatocellular carcinoma tumour burden score to stratify prognosis after resection

Tsilimigras

Moris

Hyer

et al. 2020

British Journal of Surgery

103

View full text Add to dashboard Cite

Background Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been largely adopted in clinical practice, recent studies have emphasized the need for further refinement and subclassification of this system. Methods Patients who underwent hepatectomy with curative intent for BCLC‐0, ‐A or ‐B hepatocellular carcinoma (HCC) between 2000 and 2017 were identified using a multi‐institutional database. The tumour burden score (TBS) was calculated, and overall survival (OS) was examined in relation to TBS and BCLC stage. Results Among 1053 patients, 63 (6·0 per cent) had BCLC‐0, 826 (78·4 per cent) BCLC‐A and 164 (15·6 per cent) had BCLC‐B HCC. OS worsened incrementally with higher TBS (5‐year OS 77·9, 61 and 39 per cent for low, medium and high TBS respectively; P < 0·001). No differences in OS were noted among patients with similar TBS, irrespective of BCLC stage (61·6 versus 58·9 per cent for BCLC‐A/medium TBS versus BCLC‐B/medium TBS, P = 0·930; 45 versus 13 per cent for BCLC‐A/high TBS versus BCLC‐B/high TBS, P = 0·175). Patients with BCLC‐B HCC and a medium TBS had better OS than those with BCLC‐A disease and a high TBS (58·9 versus 45 per cent; P = 0·005). On multivariable analysis, TBS remained associated with OS among patients with BCLC‐A (medium TBS: hazard ratio (HR) 2·07, 95 per cent c.i. 1·42 to 3·02, P < 0·001; high TBS: HR 4·05, 2·40 to 6·82, P < 0·001) and BCLC‐B (high TBS: HR 3·85, 2·03 to 7·30; P < 0·001) HCC. TBS could also stratify prognosis among patients in an external validation cohort (5‐year OS 79, 51·2 and 28 per cent for low, medium and high TBS respectively; P = 0·010). Conclusion The prognosis of patients with HCC varied according to the BCLC stage but was largely dependent on the TBS.

show abstract

“…Due to improvements in surgery, radiotherapy and chemotherapy, the prognosis of liver cancer patients has gradually improved, though the median survival period of liver cancer patients is currently approximately 12 months, and the 5-year survival rate remains less than 15%. 1 Therefore, new anti-hepatocellular carcinoma drugs are urgently needed to improve the prognosis of patients with liver cancer.…”

Section: Introductionmentioning

confidence: 99%

<p>The Acetone Indigo Red Dehydrating Agent IF203 Induces HepG2 Cell Death Through Cell Cycle Arrest, Autophagy and Apoptosis</p>

Shang¹,

Wang²,

Li³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Isatin derivatives have extensive biological activities, such as antitumor. IF203, a novel isatin derivative, has not previously been reported to have antitumor activity. Methods: Acid phosphatase assays (APAs) and Ki-67 immunohistochemistry were used to detect the proliferation of HepG2 cells. Transmission electron microscope (TEM) was applied to detect ultrastructural changes. Flow cytometry (FCM) was used to detect cell cycle, apoptosis, reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) of HepG2 cells in vitro. TUNEL, MMP and ROS immunofluorescence assays were applied to assess apoptosis, MMP, and ROS of HepG2 cells in vivo. Western Blotting was applied to assess the levels of apoptosis-and autophagy-related proteins. Results: In this study, in vivo and in vitro experiments showed that IF203 possesses antitumor activity. The results of APAs and Ki-67 immunohistochemistry demonstrated that IF203 could inhibit the proliferation of HepG2 cells. Cell cycle assays, downregulation of Cyclin B1 and Cdc2, and upregulation of P53 suggested that IF203 could lead to G2/M cell cycle arrest. In addition, ultrastructural changes, apoptosis assays, TUNEL immunofluorescence results, upregulated expression of Bax, and downregulated expression of Bcl-2 suggest that IF203 can induce apoptosis in HepG2 cells. After IF203 treatment, intracellular ROS levels increased, MMP decreased, JC-1 green fluorescence was enhanced, and the levels of Caspase-9, Caspase-3 and Cytochrome C expression were upregulated, suggesting that IF203 could induce apoptosis of HepG2 cells through the mitochondrial apoptosis pathway. Moreover, characteristic apoptotic ultrastructural changes were accompanied by the appearance of many autophagy bubbles and upregulation of Atg5, Atg12, ULK1, Beclin-1 and LC3-II proteins, suggesting that IF203 could induce autophagy in HepG2 cells. Conclusion: This study showed that IF203 leads to the death of HepG2 cells through cell cycle arrest, apoptotic induction, and autophagy promotion.

show abstract

Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma

Abstract: Treatment strategies that include liver resection offer a survival benefit compared with non-surgical treatments for potentially resectable BCLC-B HCC.

Cited by 69 publications

References 33 publications

Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma—authors’ reply

Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma—authors’ reply

Hepatocellular carcinoma tumour burden score to stratify prognosis after resection

<p>The Acetone Indigo Red Dehydrating Agent IF203 Induces HepG2 Cell Death Through Cell Cycle Arrest, Autophagy and Apoptosis</p>

Contact Info

Product

Resources

About